Bioalliance Pharma To Complete NDA For Loramyc(R) With Data On Debossed Mucoadhesive Tablet

BioAlliance Pharma SA (Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, announced that the FDA did not accept the NDA for Loramyc® (miconazole) mucoadhesive buccal tablet (MBT) to be filed based on the lack of a tablet imprint code. Loramyc® was approved in Europe in 2007 and is currently marketed in several EU territories including France, Germany, the UK, Sweden, Finland and Denmark.

More: continued here

Filed under: Cancer on April 15th, 2009